Viral load of high-risk human papillomaviruses as reliable clinical predictor for the presence of cervical lesions

Cancer Epidemiology Biomarkers and Prevention

Volumn 22, Issue 3, 2013, Pages 406-414

  Schmitt, Markus ^a   Depuydt, Christophe ^b   Benoy, Ina ^b   Bogers, Johannes ^b   Antoine, Jerome ^c   Pawlita, Michael ^a   Arbyn, Marc ^c  

^a GERMAN CANCER RESEARCH CENTER DKFZ   (Germany)

^b Laboratory for clinical pathology (Labo Lokeren Campus Riatol)   (Belgium)

^c SCIENTIFIC INSTITUTE OF PUBLIC HEALTH   (Belgium)

Author keywords

[No Author keywords available]

Indexed keywords

ARTICLE; CONTROLLED STUDY; FEMALE; HISTOLOGY; HUMAN; HUMAN PAPILLOMAVIRUS DNA TEST; MAJOR CLINICAL STUDY; PREDICTIVE VALUE; PRIORITY JOURNAL; REAL TIME POLYMERASE CHAIN REACTION; RETROSPECTIVE STUDY; SENSITIVITY AND SPECIFICITY; UTERINE CERVIX CYTOLOGY; UTERINE CERVIX DISEASE; VIRUS LOAD; WART VIRUS;

CARCINOMA, SQUAMOUS CELL; CERVICAL INTRAEPITHELIAL NEOPLASIA; DNA, VIRAL; FEMALE; FOLLOW-UP STUDIES; HUMANS; NEOPLASM STAGING; PAPILLOMAVIRIDAE; PAPILLOMAVIRUS INFECTIONS; PROGNOSIS; REAL-TIME POLYMERASE CHAIN REACTION; RETROSPECTIVE STUDIES; RISK FACTORS; ROC CURVE; UTERINE CERVICAL NEOPLASMS; VIRAL LOAD;

EID: 84876572768     PISSN: 10559965     EISSN: None     Source Type: Journal    
DOI: 10.1158/1055-9965.EPI-12-1067     Document Type: Article

References (33)

1. Bernard HU, Burk RD, Chen Z, van Doorslaer K, Hausen H, de Villiers EM. Classification of papillomaviruses (PVs) based on 189 PV types and proposal of taxonomic amendments. Virology 2010;401:70-9.
2. Antonsson A, Forslund O, Ekberg H, Sterner G, Hansson BG. The ubiquity and impressive genomic diversity of human skin papillomaviruses suggest a commensalic nature of these viruses. J Virol 2000;74:11636-41. (Pubitemid 32222312)
3. Schiffman M, Clifford G, Buonaguro FM. Classification of weakly carcinogenic human papillomavirus types: addressing the limits of epidemiology at the borderline. Infect Agent Cancer 2009;4:8.
4. Solomon D, Davey D, Kurman R, Moriarty A, O'Connor D, Prey M, et al. The 2001 Bethesda System: terminology for reporting results of cervical cytology. Jama 2002;287:2114-9. (Pubitemid 34437346)
5. Meijer CJ, Berkhof H, Heideman DA, Hesselink AT, Snijders PJ. Validation of high-risk HPV tests for primary cervical screening. J Clin Virol 2009;46 Suppl 3:S1-4.
6. Arbyn M, Anttila A, Jordan J, Ronco G, Schenck U, Segnan N, et al. European Guidelines for Quality Assurance in Cervical Cancer Screening. Second edition-summary document. Ann Oncol: Off J Euro Soc Med Oncol/ESMO 2010;21:448-58.
7. Castle PE, Schiffman M, Wheeler CM. Hybrid capture 2 viral load and the 2-year cumulative risk of cervical intraepithelial neoplasia grade 3 or cancer. Am J Obstet Gynecol 2004;191:1590-7. (Pubitemid 39491184)
8. Gravitt PE, Kovacic MB, Herrero R, Schiffman M, Bratti C, Hildesheim A, et al. High load for most high risk human papillomavirus genotypes is associated with prevalent cervical cancer precursors but only HPV16 load predicts the development of incident disease. Int J Cancer 2007;121:2787-93. (Pubitemid 350136428)
9. Arbyn M, Benoy I, Simoens C, Bogers J, Beutels P, Depuydt C. Prevaccination distribution of human papillomavirus types in women attending at cervical cancer screening in Belgium. Cancer Epidemiol Biomarkers Prev 2009;18:321-30.
10. Hesselink AT, Berkhof J, Heideman DA, Bulkmans NW, van Tellingen JE, Meijer CJ, et al. High-risk human papillomavirus DNA load in a population-based cervical screening cohort in relation to the detection of high-grade cervical intraepithelial neoplasia and cervical cancer. Int J Cancer 2009;124:381-6.
11. Snijders PJ, Hogewoning CJ, Hesselink AT, Berkhof J, Voorhorst FJ, Bleeker MC, et al. Determination of viral load thresholds in cervical scrapings to rule out CIN 3 in HPV 16, 18, 31 and 33-positive women with normal cytology. Int J Cancer 2006;119:1102-7. (Pubitemid 44116920)
12. Hesselink AT, van den Brule AJ, Groothuismink ZM, Molano M, Berkhof J, Meijer CJ, et al. Comparison of three different PCR methods for quantifying human papillomavirus type 16 DNA in cervical scrape specimens. J Clin Microbiol 2005;43:4868-71. (Pubitemid 41298298)
13. Arbyn M, Kaufmann A, Gissmann L, Schneider A. Highlights of the 27th International Papillomavirus Conference and Clinical Workshop (Berlin, 17-22 September, 2011)-part II. Future Virol 2012;7:19-24.
14. Meijer CJ, Berkhof J, Castle PE, Hesselink AT, Franco EL, Ronco G, et al. Guidelines for human papillomavirus DNA test requirements for primary cervical cancer screening in women 30 years and older. Int J Cancer 2009;124:516-20.
15. Vassilakos P, Griffin S, Megevand E, Campana A. CytoRich liquidbased cervical cytologic test. Screening results in a routine cytopathology service. Acta Cytol 1998;42:198-202.
16. Benoy IH, Vanden Broeck D, Ruymbeke MJ, Sahebali S, Arbyn M, Bogers JJ, et al. Prior knowledge of HPV status improves detection of CIN2+ by cytology screening. Am J Obstet Gynecol 2011;205: 569. e1-7.
17. Arbyn M, Van Oyen H. Cervical cancer screening in Belgium. Eur J Cancer. 2000;36:2191-7.
18. Depuydt CE, Vereecken AJ, Salembier GM, Vanbrabant AS, Boels LA, van Herck E, et al. Thin-layer liquid-based cervical cytology and PCR for detecting and typing human papillomavirusDNAin Flemishwomen. Br J Cancer 2003;88:560-6. (Pubitemid 36363365)
19. Depuydt CE, Benoy IH, Bailleul EJ, Vandepitte J, Vereecken AJ, Bogers JJ. Improved endocervical sampling and HPV viral load detection by Cervex-Brush Combi. Cytopathology 2006;17:374-81. (Pubitemid 44808532)
20. Moberg M, Gustavsson I, Gyllensten U. Type-specific associations of human papillomavirus load with risk of developing cervical carcinoma in situ. Int J Cancer 2004;112:854-9. (Pubitemid 39435271)
21. Schmitt M, Dondog B, Waterboer T, Pawlita M. Homogeneous amplification of genital human alpha papillomaviruses by PCR using novel broad-spectrum GP5+ and GP6+ primers. J Clin Microbiol 2008;46: 1050-9. (Pubitemid 351380000)
22. Schmitt M, Bravo IG, Snijders PJ, Gissmann L, Pawlita M, Waterboer T. Bead-based multiplex genotyping of human papillomaviruses. J Clin Microbiol 2006;44:504-12. (Pubitemid 43222244)
23. Schmitt M, Depuydt C, Benoy I, Bogers J, Antoine J, Arbyn M, et al. Prevalence and viral load of 51 genital human papillomavirus types and three subtypes. Int J Cancer 2012 Oct 4. doi:10.1002/ijc.27891. [Epub ahead of print].
24. Schmitt M, Dondog B, Waterboer T, Pawlita M, Tommasino M, Gheit T. Abundance of multiple high-risk human papillomavirus (HPV) infections found in cervical cells analyzed by use of an ultrasensitive HPV genotyping assay. J Clin Microbiol 2010;48:143-9.
25. Constandinou-Williams C, Collins SI, Roberts S, Young LS, Woodman CB, Murray PG. Is human papillomavirus viral load a clinically useful predictive marker? A longitudinal study. Cancer Epidemiol Biomarkers Prev 2010;19:832-7.
26. Swan DC, Tucker RA, Tortolero-Luna G, Mitchell MF, Wideroff L, Unger ER, et al. Human papillomavirus (HPV) DNA copy number is dependent on grade of cervical disease and HPV type. J Clin Microbiol 1999;37: 1030-4. (Pubitemid 29140610)
27. Boulet GA, Benoy IH, Depuydt CE, Horvath CA, Aerts M, Hens N, et al. Human papillomavirus 16 load and E2/E6 ratio in HPV16-positive women: biomarkers for cervical intraepithelial neoplasia >or 1/4 2 in a liquid-based cytology setting? Cancer Epidemiol Biomarkers Prev 2009;18:2992-9.
28. Baldwin P, Laskey R, Coleman N. Translational approaches to improving cervical screening. Nat Rev 2003;3:217-26. (Pubitemid 37328873)
29. StolerMH. HPV for cervical cancer screening: is the era of the molecular pap smear upon us? J Histochem Cytochem 2001;49:1197-8. (Pubitemid 32800545)
30. Fahey MT, Irwig L, Macaskill P. Meta-analysis of Pap test accuracy.Am J Epidemiol 1995;141:680-9.
31. Wright TC Jr, Schiffman M, Solomon D, Cox JT, Garcia F, Goldie S, et al. Interim guidance for the use of human papillomavirus DNAtesting as an adjunct to cervical cytology for screening. Obstet Gynecol 2004;103:304-9.
32. Schmitt M, Dalstein V, Waterboer T, Clavel C, Gissmann L, Pawlita M. Diagnosing cervical cancer and high-grade precursors by HPV16 transcription patterns. Cancer Res 2010;70:249-56.
33. IARC. Agents Classified by the IARC Monographs, Volumes 1-100. 2012. Available from: http://monographs.iarc.fr/ENG/Monographs/vol100B/index.php